Razi Cov Pars () is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine. It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.
Medical uses It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).
Pharmacology Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.
Manufacturing It's planned to produce one million doses of the vaccine each month as of September 2021.
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.
History
Clinical trials +Clinical trials of Razi Cov ParsPhaseRegistration numberStartNumber of participantsAge of participantsRefTotalVaccinePlaceboIIRCT20201214049709N121 January 202113330 (5 μg/200 μL) 30 (10 μg/200 μL)
30 (20 μg/200 μL)30 (placebo) 13 (sentinel)18-50 yearsIIIRCT20201214049709N213 April 202150018-70 yearsIIIIRCT20201214049709N3 29 August 202141,12820,5640 (placebo) 20,564 (Sinopharm BIBP vaccine)18+ years
See also Pharmaceuticals in Iran COVID-19 pandemic in Iran COVID-19 vaccine clinical research
References
Further reading